Vetsecure Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 30-07-2024
- Paid Up Capital ₹ 0.10 M
as on 30-07-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -16.28%
(FY 2023)
- Profit -44.05%
(FY 2023)
- Ebitda -44.05%
(FY 2023)
- Net Worth 9.64%
(FY 2023)
- Total Assets -11.03%
(FY 2023)
About Vetsecure Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Prem Kumar and Geeta Rani serve as directors at the Company.
- CIN/LLPIN
U24235RJ2014PTC046470
- Company No.
046470
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Vetsecure Pharmaceuticals Private Limited offer?
Vetsecure Pharmaceuticals Private Limited offers a wide range of products and services, including Bird Food, Poultry & Animal Food, Animal Feed Supplement, Animal Medicines & Health Care, Animal Nutraceuticals, Fertilizers and Soil Additives, Micronutrient Fertilizers, Veterinary Medicines.
Who are the key members and board of directors at Vetsecure Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prem Kumar  | Director | 01-Nov-2014 | Current |
| Geeta Rani | Additional Director | Current |
Financial Performance of Vetsecure Pharmaceuticals.
Vetsecure Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 16.28% decrease. The company also saw a substantial fall in profitability, with a 44.05% decrease in profit. The company's net worth moved up by a moderate rise of 9.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vetsecure Pharmaceuticals?
In 2023, Vetsecure Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Vetsecure Pharmaceuticals?
Unlock and access historical data on people associated with Vetsecure Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vetsecure Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vetsecure Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
